Research Links Sglt2 Inhibitors To Increased Risk For Vaginal Candidiasis | Latest News RSS feed

Research Links Sglt2 Inhibitors To Increased Risk For Vaginal Candidiasis - Latest News


Research links SGLT2 inhibitors to increased risk for vaginal candidiasis

A study in the Journal of Diabetes Investigation showed that women with type 2 diabetes were at an increased risk for vaginal candidiasis and symptomatic vaginitis after six months of initiating SGLT2 ... read more

Janssen's first-in-class diabetes drug Invokana wins US approval

A sodium-glucose co-transporter 2 (SGLT2) inhibitor, Invokana works by blocking ... The most common side effects of Invokana are vaginal yeast infection (vulvovaginal candidiasis) and urinary tract in... read more

Bolstering your armamentarium with SGLT2 inhibitors

5 However, SGLT2 inhibition reduces only 30% to 50% of the glucose load, and it has been speculated that this is due to increased compensatory SGLT1 activity. 6 Efficacy. Currently, three SGLT2 inhibi... read more

Looking for another news?


Lexicon Pharmaceuticals' CEO Discusses LX4211 Top-line Data from Phase 2b Trial (Transcript)

If you would like to view the slides for today's call, please access the Lexicon website at www.lexpharma.com, you will see a link on the home ... is a first in class inhibitor of sodium-dependent glu... read more


European Medicines Agency issues statement on link between SGLT2 inhibitors and diabetic ketoacidosis

However, a study published in the journal Diabetes Care identified "an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations [...] associated with ... read more

FDA Approves 1st in New Class of Type 2 Diabetes Drugs

FRIDAY, March 29, 2013 (HealthDay News) -- The first in a new class of type 2 diabetes drugs was approved Friday by the ... to a class of drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitor... read more

INVOKANA® (canagliflozin) Demonstrates Cardiovascular (CV) Risk Reductions in Type 2 Diabetes Patients With and Without a History of Prior CV Events

Nov. 14, 2017 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced a new analysis from the CANVAS Program, which showed INVOKANA ® (canagliflozin) demonstrated a reduced risk ... read more

Approaches to the Management of Invasive Fungal Infections in Hematologic Malignancy and Hematopoietic Cell Transplantation

Patients with hematologic malignancy and hematopoietic cell transplant (HCT) recipients are at increased risk for invasive fungal infection (IFI) as a result of immunosuppression or organ damage stemm... read more

FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes

RARITAN, N.J., Dec. 12, 2013 /PRNewswire/ -- Janssen Research & Development ... is an oral medication that selectively inhibits sodium glucose co-transporter 2 (SGLT2), a carrier responsible for the r... read more

SCYNEXIS Reports Second Quarter 2017 Financial Results and Provides Company Update

“During the quarter, we commenced enrollment in our Phase 2 trial for vulvovaginal candidiasis ... p.m. MT Title of the Poster Presentation: Vaginal Concentrations of SCY-078, a Novel Glucan Synthase ... read more

SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update

Key Messages: Women suffering from vaginal yeast infections (vulvovaginal candidiasis or VVC ... with net working capital of $39.1 million. Research and development expenses decreased to $3.9 million ... read more

Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for type 2 diabetes mellitus

A novel class of medications, sodium-glucose cotransporter-2 inhibitors, presents an additional ... paper suggested several potential mechanisms by which SGLT2 inhibitors may increase the risk of keto... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us